More than half a million people with cancer will die this year; our mission is to be your one source to improve people's health and lives.
From hundreds of preclinical tumor models and cell line assays to oncology clinical trials & post-market studies, we can help you get your next breakthrough cancer drug or precision medicine treatment to those who desperately need it.
In the last five years, our expertise, insights and market impact have been demonstrated in excess of 975 oncology studies (300 in immuno-oncology) across nearly 19,000 sites in 83 countries with more than 104,000 oncology patients.
Featured screening & diagnostic tests:
Embrace a personalized medicine approach that targets therapies to specific subsets of patients and begins in the preclinical phase of drug development.
Utilize biomarkers in clinical oncology development to provide key data for earlier decision making as well as patient and site selection
Co-develop a drug with an oncology companion diagnostics to help identify patients most likely to benefit from your next cancer breakthrough
The industry has approached immuno-oncology from many angles, thus requiring identification, development and refinement of models capable of recapitulating optimal biological dynamics along with the associated and relevant endpoints.
Making gains in precision medicine for clinical trials requires novel methods to quickly test and target the right therapy to the right individual. In addition to dozens of late-stage immuno-oncology clinical trials, we have also supported more than 70% of all FDA-approved companion diagnostic products.
Let's start a conversation
Contact Us
Covance by Labcorp is a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries.
COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.
.png){kind=icon}